EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial

Biswa Ranjan Mishra, Debadatta Mohapatra, Tathagata Biswas, Archana Mishra, Sahadeb Panigrahi, Rituparna Maiti

Journal of Affective Disorders · 2025

DOI: 10.1016/j.jad.2025.119891 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Biswa Ranjan Mishra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India. Electronic address: brm1678@gmail.com. Hauptthemen laut MEDLINE: Benzothiazoles, Amantadine, Depressive Disorder, Treatment-Resistant, Antidepressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Augmentation strategies for treatment-resistant depression (TRD) are limited, with strongest evidence for atypical antipsychotics. Given emerging insights into the neurobiology of TRD, new drug classes merit investigation. We hypothesised that augmentation with amantadine (NMDA antagonist) and pramipexole (dopamine agonist) would show comparable efficacy and safety to quetiapine in TRD. METHODS: In this open-label trial, 150 patients with TRD were equally randomised to receive amantadine 200 mg/day, pramipexole 0.375 mg/day, or quetiapine 100 mg/day, as augmentation to ongoing sertraline. The Hamilton Depression Rating Scale (HAM-D21) and Clinical Global Impression (CGI)-Severity and CGI-Improvement scales were assessed and compared within and between the groups at baseline, four, and eight weeks. Serum Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) were measured at baseline, four and eight weeks to evaluate and compare neurotrophic changes between the groups alongside clinical response. RESULTS: Mixed-model ANOVA revealed significant HAM-D and CGI-S reductions in all three groups over eight weeks (p 0.05). BDNF and NGF levels increased significantly within each group (p 0.05). The three groups reported similar occurence of adverse events (p = 0.184). CONCLUSION: Augmentation with amantadine and pramipexole were safe and effective in TRD. Additionally, pramipexole showed better efficacy to amantadine and quetiapine. Clinical improvements corroborated with improved BDNF and NGF levels. However, larger multi-centric studies are warranted for generalisability. (ClinicalTrials.gov: NCT04936126).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzothiazolesAmantadineDepressive Disorder, Treatment-ResistantAntidepressive AgentsDopamine AgonistsHumansPramipexoleMaleFemaleMiddle AgedQuetiapine FumarateBrain-Derived Neurotrophic FactorDrug Therapy, CombinationAdultTreatment OutcomeNerve Growth FactorSertralineAntipsychotic AgentsAgedPsychiatric Status Rating Scales

Stichwörter der Autor:innen

AmantadineClinical trialDouble-blind RCTPramipexoleQuetiapineTreatment-resistant depression

Substanzen

PramipexoleBenzothiazolesAmantadineQuetiapine FumarateBrain-Derived Neurotrophic FactorAntidepressive AgentsDopamine AgonistsNerve Growth FactorSertralineAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India. Electronic address: brm1678@gmail.com.
  • Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.
  • Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, Odisha, India.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Mishra, B. R., Mohapatra, D., Biswas, T., Mishra, A., Panigrahi, S., & Maiti, R. (2025). Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119891

Vancouver

Mishra BR, Mohapatra D, Biswas T, Mishra A, Panigrahi S, Maiti R. Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119891

BibTeX
@article{Mishra2025,
  author = {Mishra, Biswa Ranjan and Mohapatra, Debadatta and Biswas, Tathagata and Mishra, Archana and Panigrahi, Sahadeb and Maiti, Rituparna},
  title = {Comparative efficacy of antidepressant augmentation with amantadine vs pramipexole in treatment-resistant unipolar depression: A randomised controlled trial},
  journal = {Journal of Affective Disorders},
  year = {2025},
  doi = {10.1016/j.jad.2025.119891}
}
Kostenlos starten →